Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Friday.

A number of other equities research analysts have also weighed in on MCRB. Canaccord Genuity Group reaffirmed a “buy” rating and set a $10.00 price target on shares of Seres Therapeutics in a report on Thursday, November 14th. Chardan Capital restated a “buy” rating and set a $1.25 target price on shares of Seres Therapeutics in a research note on Wednesday, November 13th. Finally, JPMorgan Chase & Co. cut Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $5.08.

Seres Therapeutics Stock Down 0.9 %

NASDAQ MCRB opened at $0.83 on Friday. Seres Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $1.53. The business has a 50 day moving average price of $0.85 and a two-hundred day moving average price of $0.86. The stock has a market cap of $142.18 million, a PE ratio of -3.62 and a beta of 2.11.

Institutional Investors Weigh In On Seres Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Avantax Advisory Services Inc. grew its stake in Seres Therapeutics by 170.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 28,500 shares in the last quarter. Jane Street Group LLC lifted its holdings in Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock worth $49,000 after buying an additional 37,866 shares during the last quarter. Virtu Financial LLC grew its position in shares of Seres Therapeutics by 44.8% in the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 18,191 shares in the last quarter. Providence Wealth Advisors LLC increased its holdings in shares of Seres Therapeutics by 29.2% in the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after acquiring an additional 22,250 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of Seres Therapeutics by 20.4% during the 4th quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock valued at $218,000 after acquiring an additional 44,461 shares in the last quarter. Institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.